Catalyst
Slingshot members are tracking this event:
Infinity Announces Publication On PI3K-Gamma In Nature
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
INFI |
|
|
Additional Information
When confronted by pathogens, injury or disease, the initial response of the body's immune system comes in the form of macrophages, a type of white blood cell that express pro-inflammatory proteins called cytokines that, in turn, activate T cells, another immune cell, to attack the health threat. The macrophages then switch gears to express other cytokines that dampen T cell activation, stimulating tissue repair. In cancer, highly abundant macrophages express anti-inflammatory cytokines that induce immune suppression, leading to enhanced tumor growth.In the Nature paper, researchers pinpoint a key, suspected player: an enzyme in macrophages called PI3K-gamma. In mouse studies, they found that macrophage PI3K-gamma signaling promotes immune suppression by inhibiting activation of anti-tumor T cells. Blocking PI3K-gamma activated the immune response and significantly suppressed growth of implanted tumors in animal models. It also boosted sensitivity of some tumors to existing anti-cancer drugs and synergized with existing immune therapy to eradicate tumors. Researchers also identified a molecular signature of immune suppression and response in mice and cancer patients that may be used to track the effectiveness of immune therapy.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 19, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pi3k-gamma, Immune Suppression, Acrophage Signaling Pathways, Phosphoinositide-3-kinase, Ipi-549